Safeguarding Women from Chemical Abortion Act
- Sponsor
- Rep. Harshbarger, Diana [R-TN-1]
- Committees
- Judiciary Committee (primary)
- Last action
- Mar 12, 2026
Bottom line
The bill aims to effectively ban the use of mifepristone for abortion by withdrawing its FDA approval and creating a federal legal pathway for individuals to sue its manufacturers for alleged harm.
What it actually does
This bill mandates the withdrawal of federal approval for the drug mifepristone, which is used for the termination of intrauterine pregnancy, effective 14 days after enactment. It also establishes a new federal civil cause of action, or tort, allowing individuals to sue manufacturers of mifepristone for bodily injury or harm to mental health attributed to the drug's use, seeking compensatory and punitive damages, as well as attorney's fees.
Proponents argue
Proponents argue that the bill is necessary to protect women from the perceived dangers and harms associated with chemical abortion drugs, asserting that mifepristone poses significant health risks. They contend that withdrawing its approval is a crucial step to safeguard women's health and that establishing a federal tort provides a vital mechanism for accountability and redress for those who have suffered adverse effects.
Opponents contend
Opponents contend that this bill represents a direct political interference with the scientific authority of the Food and Drug Administration (FDA), which has deemed mifepristone safe and effective for over two decades. They argue it would severely restrict access to a safe and widely used method of abortion, potentially forcing individuals to resort to less safe options or travel long distances for care, thereby undermining reproductive healthcare access and autonomy.
The bill is short and straightforward, making it highly accessible for a reader to understand its core provisions within a short timeframe.
Section 2
Withdrawal of Approval of Mifepristone for Termination of Pregnancy
This section mandates that, 14 days after the bill becomes law, the Food and Drug Administration's (FDA) approval for mifepristone (marketed as Mifeprex or RU-486) for terminating intrauterine pregnancy will be considered withdrawn. This means it would be illegal to introduce or deliver the drug for this purpose into interstate commerce, and any labeling suggesting its use for pregnancy termination would cause the drug to be considered misbranded.
Supporters argue
Supporters argue that this provision is essential to protect women from the alleged health risks associated with mifepristone, which they claim are understated or ignored by current regulatory frameworks. They believe that removing the drug from the market for abortion purposes will prevent adverse outcomes and align federal policy with a pro-life stance.
Critics contend
Critics contend that this provision is a dangerous political overreach that disregards scientific evidence and the FDA's role as the primary arbiter of drug safety and efficacy. They argue that mifepristone has a proven safety record and that its withdrawal would severely limit reproductive healthcare options, forcing individuals to seek more invasive procedures or potentially unsafe alternatives.
Tradeoffs
The provision navigates the tension between legislative control over drug availability and the established scientific and regulatory processes of the FDA. It also highlights the conflict between those prioritizing abortion access and those prioritizing restrictions based on moral or perceived safety grounds.
Section 3
Establishment of Federal Tort for Harm from Chemical Abortion Drugs
This section creates a new federal civil liability, or 'tort,' allowing any individual who experiences bodily injury or harm to mental health (including physical, psychological, emotional, or physiological harm) due to their use of mifepristone for abortion to sue the drug's manufacturer. Successful plaintiffs could be awarded compensatory damages, punitive damages, and attorney's fees and costs. This section explicitly states it does not preempt any existing state laws offering other remedies.
These subsections specify the legal consequences of the mifepristone approval withdrawal. Section 2(2) makes the introduction or delivery of the drug into interstate commerce a violation of the Federal Food, Drug, and Cosmetic Act (FFDCA), subject to enforcement actions like seizure and injunctions. Section 2(3) declares mifepristone misbranded if its labeling suggests use for pregnancy termination.
Section 2(2) and 2(3)
Why it matters:This is standard legislative practice for defining the legal ramifications of a primary policy change. The FFDCA references are necessary for legal precision.
Case for: Supporters would argue these provisions are essential for ensuring the effective enforcement of the drug's withdrawal, providing clear legal grounds for preventing its continued distribution and use for abortion.
Case against: Opponents would view these as integral parts of the broader effort to restrict abortion access, highlighting the comprehensive nature of the proposed ban and the severe penalties for non-compliance.
Estimated impact: These provisions establish the legal framework for the complete cessation of legal mifepristone distribution for abortion in the U.S., with significant implications for manufacturers, distributors, and healthcare providers.
This subsection explicitly states that nothing in the federal tort provision (Section 3) should be interpreted to preempt any State law that offers other remedies to an individual harmed by mifepristone. This means states could still provide additional or alternative legal avenues for recourse.
Section 3(d)
Why it matters:This is a common legislative practice to clarify the relationship between federal and state law, particularly in areas where both jurisdictions might have overlapping authority. It ensures that the federal tort does not inadvertently nullify existing state protections.
Case for: Proponents would argue this ensures that the federal tort acts as a floor, not a ceiling, for legal protections, allowing states to offer even stronger remedies if they choose, thus maximizing accountability for manufacturers.
Case against: Opponents might argue that this provision could lead to a patchwork of laws and increased legal complexity for manufacturers, potentially exacerbating the chilling effect on drug development by opening up multiple fronts for litigation.
Estimated impact: This provision preserves the ability of states to legislate on tort liability related to mifepristone, potentially leading to varied legal landscapes across the country and increasing the overall legal risk for manufacturers.
This section states that nothing in the Act shall be construed to affect any provision of section 1461 of title 18, United States Code. Section 1461, often referred to as the Comstock Act, prohibits the mailing of 'obscene, lewd, or lascivious' materials, including any article or thing designed, adapted, or intended for producing abortion.
Section 4
Why it matters:This is a technical legal clarification, often placed at the end of a bill to ensure it doesn't inadvertently repeal or modify existing federal law. Its placement is standard for such clauses.
Case for: Proponents would argue this clause ensures that existing federal laws related to abortion-inducing materials, such as the Comstock Act, remain fully in effect and are not weakened by this bill. It reinforces a comprehensive approach to restricting abortion-related activities.
Case against: Opponents would highlight this clause as a deliberate effort to keep alive or potentially reactivate an archaic law (the Comstock Act) that could have far-reaching implications for the mailing of abortion-related medications and information, even beyond mifepristone, potentially impacting other forms of reproductive healthcare.
Estimated impact: This provision signals an intent to preserve or potentially expand the applicability of the Comstock Act, which could have significant implications for the interstate shipment of any abortion-related materials, not just mifepristone, potentially affecting access to care even in states where abortion remains legal.